In this study, we investigated the serum vitamin D level in overweight individuals and its correlation with the incidence of nonalcoholic fatty liver disease (NAFLD). Between May 2020 and May 2021, the Department of Gastroenterology at the People's Hospital of Henan University of Traditional Chinese Medicine treated a total of 321 outpatients and inpatients with NAFLD, who were included in the NAFLD group, while 245 healthy age- and gender-matched individuals were included in the control group. All the data were collected for the relevant indices, including fasting plasma glucose, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, alanine transaminase, and 25-hydroxy vitamin D (25[OH]D. The patients with NAFLD were divided into the normal BMI group, the overweight group, and the obese group, according to the body mass index, and the 25(OH)D levels were compared between the different groups. Spearman's correlation analysis was performed to analyze the correlation between the serum 25(OH)D level and NAFLD. Regarding the serum 25 (OH)D level, it was lower in the NAFLD group than in the control group ([18.36 + 1.41] µg/L vs [22.33 + 2.59] µg/L, t = ?5.15, P<0.001), and was lower in the overweight group than in the normal group ([18.09 ± 5.81] µg/L vs [20.60 ± 4.16] µg/L, t = 0.26, P = 0.041). The serum 25(OH)D level was thus negatively correlated with the incidence of NAFLD in overweight individuals (r = 0.625, P<0.05). In conclusion, the level of 25(OH)D decreased in patients with NAFLD with increasing BMI (normal, overweight, obese). Keywords: Nonalcoholic fatty liver disease, Vitamin D.

Department of Gastroenterology People's Hospital of Henan University of Chinese Medicine Henan University of Chinese Medicine Zhengzhou Henan Province China

Zobrazit více v PubMed

Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596–1607. doi: 10.1038/s42255-021-00501-9. PubMed DOI

Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(5):491–502. doi: 10.1080/17474124.2018.1460202. PubMed DOI

Luo H, Li J, Zhang Q, Cao P, Ren X, Fang A, et al. Obesity and the onset of depressive symptoms among middle-aged and older adults in China: evidence from the CHARLS. BMC Public Health. 2018;18(1):909. doi: 10.1186/s12889-018-5834-6. PubMed DOI PMC

Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol Baltim Md. 2019;69(6):2672–2682. doi: 10.1002/hep.30251. PubMed DOI

Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi: 10.1016/j.jhep.2017.06.003. PubMed DOI

Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. doi: 10.1016/j.molmet.2021.101238. PubMed DOI PMC

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71(5):1012–1021. doi: 10.1016/j.jhep.2019.06.031. PubMed DOI

Feghaly J, Johnson P, Kalhan A. Vitamin D and obesity in adults: a pathophysiological and clinical update. Br J Hosp Med Lond Engl 2005. 2020;81(1):1–5. doi: 10.12968/hmed.2019.0291. PubMed DOI

Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): An Update. Nutrients. 2020;12(11):3302. doi: 10.3390/nu12113302. PubMed DOI PMC

Qu YL, Wang YC, Wan JX. Association of nonalcoholic fatty liver disease with vitamin D and bone mineral density. J Clin Hepatol. 2019;35(9):2021–2025. doi: 10.3969/j.issn.1001-5256.2019.09.027. DOI

Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, et al. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(19):3407–3417. doi: 10.3748/wjg.v23.i19.3407.. doi: 10.3748/wjg.v23.i19.3407. PubMed DOI PMC

Toriniwa Y, Muramatsu M, Ishii Y, Riya E, Miyajima K, Ohshida S, et al. Pathophysiological characteristics of non-alcoholic steatohepatitis-like changes in cholesterol-loaded type 2 diabetic rats. Physiol Res. 2018;67(4):601–612. doi: 10.33549/physiolres.933784. PubMed DOI

Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, et al. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J Hepatol. 2015;62(2):405–411. doi: 10.1016/j.jhep.2014.08.040. PubMed DOI

Elkattawy HA, Elsherbini DM, Ebrahim HA, Abdullah DM, Al-Zahaby SA, Noser Y, et al. Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats. Physiol Res. 2022;71(5):615–630. doi: 10.33549/physiolres.934869. PubMed DOI PMC

Stein EM, Strain G, Sinha N, Ortiz D, Pomp A, Dakin G, et al. Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study. Clin Endocrinol (Oxf) 2009;71(2):176–183. doi: 10.1111/j.1365-2265.2008.03470.x. PubMed DOI PMC

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. PubMed DOI

Chinese Medical Association Liver Diseases Branch Fatty Liver and Alcoholic Liver Disease Group. Guidelines for the prevention and treatment of nonalcoholic fatty liver disease (updated version 2018) J Clin Hepatol. 2018;34(5):947–957.

Obesity Group and Chinese Society of Endocrinology. Consensus of Chinese adult obesity prevention experts. (In Chinese) Chinese Journal of Endocrinology and Metabolism. 2011;27:711–717.

Hurr C, Simonyan H, Morgan DA, Rahmouni K, Young CN. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. J Physiol. 2019;597(17):4565–4580. doi: 10.1113/JP277994. PubMed DOI PMC

Zhang Z, Thorne JL, Moore JB. Vitamin D and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2019;22(6):449–458. doi: 10.1097/MCO.0000000000000605. PubMed DOI

Seo JA, Cho H, Eun CR, Yoo HJ, Kim SG, Choi KM, et al. Association between visceral obesity and sarcopenia and vitamin D deficiency in older Koreans: the Ansan Geriatric Study. J Am Geriatr Soc. 2012;60(4):700–706. doi: 10.1111/j.1532-5415.2012.03887.x. PubMed DOI

Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–1199. doi: 10.1210/jc.2003-031398. PubMed DOI

Bima A, Eldakhakhny B, Nuwaylati D, Alnami A, Ajabnoor M, Elsamanoudy A. The interplay of vitamin D deficiency and cellular senescence in the pathogenesis of obesity-related co-morbidities. Nutrients. 2021;13(11):4127. doi: 10.3390/nu13114127. PubMed DOI PMC

Zhang JJ, Yu HC, Li Y, Zhang YB, Geng TT, Lu Q, et al. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study. Am J Clin Nutr. 2022;116(5):1409–1417. doi: 10.1093/ajcn/nqac260. PubMed DOI